Cargando…

Intracellular PD Modelling (PD(i)) for the Prediction of Clinical Activity of Increased Rifampicin Dosing

Increasing rifampicin (RIF) dosages could significantly reduce tuberculosis (TB) treatment durations. Understanding the pharmacokinetic-pharmacodynamics (PK–PD) of increasing RIF dosages could inform clinical regimen selection. We used intracellular PD modelling (PD(i)) to predict clinical outcomes,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aljayyoussi, Ghaith, Donnellan, Samantha, Ward, Stephen A., Biagini, Giancarlo A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630509/ https://www.ncbi.nlm.nih.gov/pubmed/31200534 http://dx.doi.org/10.3390/pharmaceutics11060278

Ejemplares similares

Intracellular Pharmacodynamic Modeling Is Predictive of the Clinical Activity of Fluoroquinolones against Tuberculosis
por: Donnellan, Samantha, et al.
Publicado: (2019)

Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration
por: Aljayyoussi, Ghaith, et al.
Publicado: (2017)

OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens
por: Aljayyoussi, Ghaith, et al.
Publicado: (2016)

Remdesivir–ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2
por: Jeffreys, Laura N., et al.
Publicado: (2022)

Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis
por: Aljayyoussi, Ghaith, et al.
Publicado: (2017)

Author Correction: Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis
por: Aljayyoussi, Ghaith, et al.
Publicado: (2018)

Arylation of Axially Chiral Phosphorothioate Salts by Dinuclear Pd(I) Catalysis
por: Chen, Xiang‐Yu, et al.
Publicado: (2019)

The harms of police frisking in times of a pandemic
por: Aljayyoussi, Ghaith
Publicado: (2020)

Pd/BIPHEPHOS is an Efficient Catalyst for the Pd‐Catalyzed S‐Allylation of Thiols with High n‐Selectivity
por: Schlatzer, Thomas, et al.
Publicado: (2019)

Identification of the functional PD-L1 interface region responsible for PD-1 binding and initiation of PD-1 signaling
por: Carter, Rachel, et al.
Publicado: (2023)

Concentrations of rifampicin in pre-dose samples in patients with pulmonary tuberculosis
por: Uchoa, Breno Kristoffer Beleza, et al.
Publicado: (2019)

Rifampicin-Loaded Mesoporous Silica Nanoparticles for the Treatment of Intracellular Infections
por: Subramaniam, Santhni, et al.
Publicado: (2019)

Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors
por: Scognamiglio, Giosue, et al.
Publicado: (2019)

High‐Performance Li‐O(2) Batteries with Trilayered Pd/MnO(x)/Pd Nanomembranes
por: Lu, Xueyi, et al.
Publicado: (2015)

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
por: Bu, Melissa T., et al.
Publicado: (2022)

The intracellular signalosome of PD-L1 in cancer cells
por: Escors, David, et al.
Publicado: (2018)

Plasma alpha‐synuclein detected by single molecule array is increased in PD
por: Ng, Adeline S. L., et al.
Publicado: (2019)

Cell wall inhibitors increase the accumulation of rifampicin in Mycobacterium tuberculosis
por: McNeil, Matthew B., et al.
Publicado: (2019)

Cytochemical flow analysis of intracellular G6PD and aggregate analysis of mosaic G6PD expression
por: Kalnoky, Michael, et al.
Publicado: (2018)

Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis
por: Rajoli, Rajith K. R., et al.
Publicado: (2020)

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing
por: Jones, Lauren, et al.
Publicado: (2022)

Chloride intracellular channel protein 2: prognostic marker and correlation with PD-1/PD-L1 in breast cancer
por: Xu, Tao, et al.
Publicado: (2020)

Increased SNX20 and PD-L1 Levels Can Predict the Clinical Response to PD-1 Inhibitors in Lung Adenocarcinoma
por: Fan, Linwei, et al.
Publicado: (2020)

‘Pd(20)Sn(13)’ revisited: crystal structure of Pd(6.69)Sn(4.31)
por: Klein, Wilhelm, et al.
Publicado: (2015)

Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors
por: Kang, Da Hyun, et al.
Publicado: (2020)

Immune Checkpoint PD-1/PD-L1 CTLA-4/CD80 are Blocked by Rhus verniciflua Stokes and its Active Compounds
por: Li, Wei, et al.
Publicado: (2019)

Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial
por: Espinosa-Pereiro, Juan, et al.
Publicado: (2022)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Formulation and Characterization of Rifampicin Microcapsules
por: Sarfaraz, MD., et al.
Publicado: (2010)

RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies
por: Pollack, Rena, et al.
Publicado: (2023)

Increase of cells expressing PD‐1 and PD‐L1 and enhancement of IFN‐γ production via PD‐1/PD‐L1 blockade in bovine mycoplasmosis
por: Goto, Shinya, et al.
Publicado: (2017)

High spin states in $^{107}$Pd, $^{108}$Pd, and $^{109}$Ag
por: Pohl, K R, et al.
Publicado: (1996)

PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
por: Surmiak, Ewa, et al.
Publicado: (2021)

Increased PD-L1 and p16 expression are common in oropharyngeal squamous cell carcinoma
por: Shestakova, Anna, et al.
Publicado: (2021)

Forecasting Clinical Dose–Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin
por: Wicha, Sebastian G., et al.
Publicado: (2018)

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg(−1) rifampicin
por: te Brake, Lindsey H.M., et al.
Publicado: (2021)

Pd-Catalyzed Suzuki-Miyaura Cross-Coupling of Pentafluorophenyl Esters
por: Buchspies, Jonathan, et al.
Publicado: (2018)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_go1tbu640d47k7bhauotc6lkft